Intellijoint Surgical Inc passes US FDA's clearance for Revision THA with intellijoint HIP surgery.
M2 EQUITYBITES-November 2, 2017-Intellijoint Surgical Inc passes US FDA's clearance for Revision THA with intellijoint HIP surgery
(C)2017 M2 COMMUNICATIONS http://www.m2.com
Medical technology company Intellijoint Surgical reported on Wednesday the receipt of the US Food and Drug Administration's (FDA) clearance for revision Total Hip Arthroplasty (THA) with its intellijoint HIP System for proper positioning of orthopaedic implants during revision surgery.
The company said the intellijoint HIP provides surgeons with precise measurements for cup position, leg length and offset for THA, requires no pre-operative or intra-operative imaging as well as can be used with any implant manufacturer and for any primary or revision THA.
In conjunction, the intellijoint HIP, which is a 3D Mini-Optical Navigation System, is available for Anterior, Posterior and Lateral approaches and can be used on primary and now revision THA. This milestone supports Intellijoint Surgical's mission of making intellijoint HIP accessible to every surgeon and every patient.
According to the company, the revision indication provides surgeons with the ability to evaluate existing THA components to inform intra-operative decision making as well as the possibility to leave existing components in place can greatly reduce risk to the patient and can contain cost for the hospital.
At the upcoming American Association of Hip and Knee Surgeons (AAHKS) annual meeting (booth 100) in Dallas, Texas from 3 -4 November 2017, the company will provide an update on the cutting-edge technology behind intellijoint HIP.
((Comments on this story may be sent to firstname.lastname@example.org))
|Printer friendly Cite/link Email Feedback|
|Publication:||M2 EquityBites (EQB)|
|Date:||Nov 2, 2017|
|Previous Article:||NCC appoints Acting General Counsel.|
|Next Article:||Seaboard reports increased net earnings for Q3 2017 year over year and dividend of USD1.50 per share.|